WO2001064196A3 - Farnesyl protein transferase inhibitor combinations with vinca alkaloids - Google Patents

Farnesyl protein transferase inhibitor combinations with vinca alkaloids Download PDF

Info

Publication number
WO2001064196A3
WO2001064196A3 PCT/EP2001/002165 EP0102165W WO0164196A3 WO 2001064196 A3 WO2001064196 A3 WO 2001064196A3 EP 0102165 W EP0102165 W EP 0102165W WO 0164196 A3 WO0164196 A3 WO 0164196A3
Authority
WO
WIPO (PCT)
Prior art keywords
transferase inhibitor
vinca alkaloids
protein transferase
farnesyl protein
inhibitor combinations
Prior art date
Application number
PCT/EP2001/002165
Other languages
French (fr)
Other versions
WO2001064196A2 (en
Inventor
Ivan David Horak
Christopher J Bowden
Original Assignee
Janssen Pharmaceutica Nv
Ivan David Horak
Christopher J Bowden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Ivan David Horak, Christopher J Bowden filed Critical Janssen Pharmaceutica Nv
Priority to JP2001563093A priority Critical patent/JP2003525236A/en
Priority to AU2001242434A priority patent/AU2001242434A1/en
Priority to EP01915297A priority patent/EP1263437A2/en
Priority to CA002397475A priority patent/CA2397475A1/en
Publication of WO2001064196A2 publication Critical patent/WO2001064196A2/en
Publication of WO2001064196A3 publication Critical patent/WO2001064196A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is concerned with combinations of a farnesyl transferase inhibitor and a vinca alkaloid for inhibiting the growth of tumor cells and useful in the treatment of cancer.
PCT/EP2001/002165 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with vinca alkaloids WO2001064196A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001563093A JP2003525236A (en) 2000-02-29 2001-02-26 Combination of a farnesyl protein transferase inhibitor with vinca alkaloids
AU2001242434A AU2001242434A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with vinca alkaloids
EP01915297A EP1263437A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with vinca alkaloids
CA002397475A CA2397475A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with vinca alkaloids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200698 2000-02-29
EP00200698.9 2000-02-29

Publications (2)

Publication Number Publication Date
WO2001064196A2 WO2001064196A2 (en) 2001-09-07
WO2001064196A3 true WO2001064196A3 (en) 2002-03-21

Family

ID=8171117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002165 WO2001064196A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with vinca alkaloids

Country Status (5)

Country Link
EP (1) EP1263437A2 (en)
JP (1) JP2003525236A (en)
AU (1) AU2001242434A1 (en)
CA (1) CA2397475A1 (en)
WO (1) WO2001064196A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
WO2014062667A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
HUE035335T2 (en) 2012-10-16 2018-05-02 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016443A1 (en) * 1995-10-31 1997-05-09 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 2-quinolone derivatives
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998040383A1 (en) * 1997-03-10 1998-09-17 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles
WO1998049157A1 (en) * 1997-04-25 1998-11-05 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
WO1999032114A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000001382A1 (en) * 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016443A1 (en) * 1995-10-31 1997-05-09 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 2-quinolone derivatives
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998040383A1 (en) * 1997-03-10 1998-09-17 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles
WO1998049157A1 (en) * 1997-04-25 1998-11-05 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
WO1999032114A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000001382A1 (en) * 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU M ET AL: "Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in huma tumor xenograft models and wap-ras transgenic mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 21, 1 November 1998 (1998-11-01), pages 4947 - 4956, XP002096891, ISSN: 0008-5472 *
SCHELLENS J H M ET AL: "PHASE I AND PHARMACOLOGIC STUDY WITH THE NOVEL FARNESYLTRANSFERASE INHIBITOR (FTI) R15777", SHIPBUILDING AND SHIPPING RECORD, IP INDUSTRIAL PRESS LTD. LONDON, GB, vol. 40, March 1999 (1999-03-01), pages 724, XP000952727 *

Also Published As

Publication number Publication date
AU2001242434A1 (en) 2001-09-12
CA2397475A1 (en) 2001-09-07
EP1263437A2 (en) 2002-12-11
WO2001064196A2 (en) 2001-09-07
JP2003525236A (en) 2003-08-26

Similar Documents

Publication Publication Date Title
WO2001064194A3 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064246A3 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
WO2001064226A3 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064198A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064252A3 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
WO2001064199A3 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
WO2001064218A3 (en) Farnesyl protein transferase inhibitor combinations
WO2001064195A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
AU1783800A (en) Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer
WO2001064217A3 (en) Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
WO2001064196A3 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2679099A (en) Methods for designing inhibitors of serine/threonine kinases and tyrosine kinases
AU2002236527A1 (en) Nutrient supplements and methods for treating autism and for preventing the onset of autism
AU2002226069A1 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
AU6340600A (en) Telomerase inhibitors and methods of their use
MY117961A (en) Inhibitors of farnesyl protein transferase
WO2002030353A3 (en) NF-λB INHIBITORS
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
UA66793C2 (en) Leptin as inhibitor of tumor growth
WO2001064197A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2002256085A1 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
AU2001264769A1 (en) Induction of apoptosis and cell growth inhibition by protein 4.33
AU6385800A (en) Archaeal replication accessory factors and methods of use
NO20005680L (en) Combinations of protein farnesyl transferase and HMG CoA reductase inhibitors and their use in the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2397475

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 563093

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10220398

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001915297

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001915297

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001915297

Country of ref document: EP